DE69938148D1 - Verfahren zur verabreichung von einer verbindung an mehrfachresistente zellen - Google Patents

Verfahren zur verabreichung von einer verbindung an mehrfachresistente zellen

Info

Publication number
DE69938148D1
DE69938148D1 DE69938148T DE69938148T DE69938148D1 DE 69938148 D1 DE69938148 D1 DE 69938148D1 DE 69938148 T DE69938148 T DE 69938148T DE 69938148 T DE69938148 T DE 69938148T DE 69938148 D1 DE69938148 D1 DE 69938148D1
Authority
DE
Germany
Prior art keywords
therapeutic compound
composition
administering
carrier
connection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69938148T
Other languages
English (en)
Other versions
DE69938148T2 (de
Inventor
Alberto A Gabizon
Samuel Zalipsky
Dorit Goren-Rubel
Aviva T Horowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Alza Corp
Original Assignee
Hadasit Medical Research Services and Development Co
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co, Alza Corp filed Critical Hadasit Medical Research Services and Development Co
Application granted granted Critical
Publication of DE69938148D1 publication Critical patent/DE69938148D1/de
Publication of DE69938148T2 publication Critical patent/DE69938148T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69938148T 1998-12-18 1999-12-17 Verfahren zur verabreichung von einer verbindung an mehrfachresistente zellen Expired - Fee Related DE69938148T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11300498P 1998-12-18 1998-12-18
US113004P 1998-12-18
PCT/US1999/030230 WO2000035422A2 (en) 1998-12-18 1999-12-17 Method of administering a compound to multi-drug resistant cells

Publications (2)

Publication Number Publication Date
DE69938148D1 true DE69938148D1 (de) 2008-03-27
DE69938148T2 DE69938148T2 (de) 2009-02-26

Family

ID=22347057

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69938148T Expired - Fee Related DE69938148T2 (de) 1998-12-18 1999-12-17 Verfahren zur verabreichung von einer verbindung an mehrfachresistente zellen

Country Status (12)

Country Link
US (2) US20040161457A1 (de)
EP (1) EP1140022B8 (de)
JP (1) JP2002532407A (de)
AT (1) ATE385778T1 (de)
AU (1) AU769569B2 (de)
CA (1) CA2353593A1 (de)
DE (1) DE69938148T2 (de)
ES (1) ES2302391T3 (de)
HK (1) HK1040633A1 (de)
IL (1) IL143555A0 (de)
MX (1) MXPA01006201A (de)
WO (1) WO2000035422A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
CA2404737C (en) 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
JP4922824B2 (ja) * 2000-04-03 2012-04-25 参天製薬株式会社 送達性物質およびそれを利用した薬物デリバリーシステム
WO2004056323A2 (en) * 2002-12-19 2004-07-08 Alza Corporation Method of treating angiogenic tissue growth
US7601332B2 (en) 2003-01-27 2009-10-13 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CN100423778C (zh) * 2003-11-25 2008-10-08 上海复旦张江生物医药股份有限公司 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用
EP1789391B1 (de) 2004-07-23 2017-06-28 Endocyte, Inc. Zweiwertige linker und konjugate davon
US20070292497A1 (en) * 2006-05-04 2007-12-20 Martin Francis J Method for treating micrometastatic tumors
AU2008224988A1 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
PL2308514T3 (pl) * 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
US20120100206A1 (en) 2009-06-11 2012-04-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
ES2819059T3 (es) 2011-07-13 2021-04-14 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Liposomas que encapsulan conjuntamente un bifosfonato y un agente anfipático
EP2789348B1 (de) 2011-12-07 2021-08-04 Universidade do Minho Liposomen und entsprechendes herstellungsverfahren
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
GB201215289D0 (en) 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
US9950074B2 (en) * 2012-10-12 2018-04-24 Georg-August-Universität Göttingen Stiftung Öffenlichen Rechts, Universitätsmedizin Composition and delivery vehicle for active agents and methods therefor
SG11201502896XA (en) 2012-10-16 2015-05-28 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using
CN106420615B (zh) * 2016-07-05 2021-01-05 广东药科大学 一种靶向脂质体骨架材料及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5804445A (en) * 1996-01-11 1998-09-08 Board Of Regents, The University Of Texas System High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor
WO1998013072A1 (en) * 1996-09-24 1998-04-02 Thomas Jefferson University Compositions for and methods of treating multiple drug resistance
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6162810A (en) * 1997-11-17 2000-12-19 The Regents Of The University Of California Inadone and tetralone compounds for inhibiting cell proliferation
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato
PL1684763T3 (pl) * 2003-09-24 2008-11-28 Wyeth Corp 6-arylo-7-halogeno-imidazo[1,2-a]pirymidyny jako środki przeciwnowotworowe

Also Published As

Publication number Publication date
WO2000035422A2 (en) 2000-06-22
EP1140022A2 (de) 2001-10-10
ATE385778T1 (de) 2008-03-15
JP2002532407A (ja) 2002-10-02
DE69938148T2 (de) 2009-02-26
US20060062842A1 (en) 2006-03-23
MXPA01006201A (es) 2003-06-06
EP1140022B8 (de) 2008-10-15
HK1040633A1 (en) 2002-06-21
ES2302391T3 (es) 2008-07-01
AU1940400A (en) 2000-07-03
CA2353593A1 (en) 2000-06-22
WO2000035422A3 (en) 2000-10-12
AU769569B2 (en) 2004-01-29
US20040161457A1 (en) 2004-08-19
IL143555A0 (en) 2002-04-21
EP1140022B1 (de) 2008-02-13

Similar Documents

Publication Publication Date Title
DE69938148D1 (de) Verfahren zur verabreichung von einer verbindung an mehrfachresistente zellen
WO1998016202B1 (en) Fusogenic liposome composition and method
BR9914601A (pt) Inibidor de topoisomerase capturado por lipossoma
EP0887075A3 (de) Klebstoffmasse zur transdermalen Verabreichung von stark weichmachenden Wirkstoffen
CA2193502A1 (en) Sphingosomes for enhanced drug delivery
EP1163902A3 (de) Einen hydrophilen oder als Salz vorliegenden Arzneiwirkstoff enthaltende transdermale Zubereitung
DE69721845D1 (de) Orale morphinzubereitung in teilchenform
FI971776A (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
CA2439500A1 (en) Drug delivery system for hydrophobic drugs
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
WO2000007979A3 (en) Compounds and compositions for delivering active agents
FR2732967B1 (fr) 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
WO2001045641A3 (en) Inhibitors of thrombin induced platelet aggregation
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
CA2202531A1 (en) Lyophilizate of lipid complex of water insoluble camptothecins
JP2002532407A5 (de)
WO2008038291A1 (en) Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
Sharma et al. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers
WO1998030709A3 (en) Non-immunogenic prodrugs and selectable markers for use in gene therapy
DE69935526D1 (de) Supramolekulare komplexe enthaltende arzneimittel
WO2004112717A3 (en) Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
EP0799618A3 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
HUP0401386A2 (hu) Kationos dextránszármazékok alkalmazása dóziskorlátozó szervek védelmére alkalmas gyógyszerkészítmények előállítására
ATE300947T1 (de) Behandlung von erkrankungen mit zystenbildung
Mayhew Interactions in Liposomal-Drug Delivery in Vivo and in Vitro

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ALZA CORP., MOUNTAIN VIEW, CALIF., US

Owner name: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPM, IL

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee